Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth H1 Revenues Fall 29 Percent

NEW YORK (GenomeWeb) — MDxHealth today reported that its total revenues for the first half of 2018 dropped 29 percent year over year while product and service revenues grew 38 percent.

For the six-month period ended June 30, MDxHealth posted total revenues of $17.2 million, versus $24.3 million in the same period the year before. Revenues for the first half of 2017, however, included $12.1 million from the one-time sale of colorectal cancer-related patents to Exact Sciences.

Total product and service revenues in the first half of 2018 climbed to $16.6 million from $12.0 million, with sales of the company's SelectMDx and ConfirmMDx prostate cancer tests increasing nearly 29 percent to $15.3 million from $11.9 million.

Revenues from ConfirmMDx — which is designed to address false-negative biopsy concerns and is sold only in the US — accounted for 92 percent of total H1 product revenues, with patient test volume rising 11 percent to 11,139. Meanwhile, global volume of SelectMDx — which is used to identify patients at increased risk for aggressive disease —  rose 67 percent year over year to 8,980 in the first half of 2018.

MDxHealth reported a H1 net loss of $15.1 million, or $.27 per share, versus a year-ago profit of $538,000, or $.01 per share — a change the company said reflects the impact of the Exact Sciences payment last year.

Operating expenses during the first six months of 2018 rose 36 percent to $25.5 million from $18.7 million as MDxHealth continued development of new products such as InformMDx — a tissue-based test to stratify prostate cancer patients according to risk of disease progression — and MonitorMDx — a liquid biopsy designed to guide clinical decision-making for castration-resistant prostate cancer.

At the end of June, Herstal, Belgium-based MDxHealth had cash and cash equivalents totaling $40.9 million.

"We have made good operational progress during the first half of 2018, and are pleased with the healthy double-digit growth of overall clinical testing volumes," MDxHealth CEO Jan Groen said in a statement. "Throughout the period, we continued to deliver on our stated four strategic objectives," which include driving provider and payor adoption of the company's tests; expanding clinical indications for SelectMDx; porting its tests onto in vitro diagnostic sample-to-answer platforms; and partnering with pharmaceutical companies.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.